Post-earnings recap
Reported
Tue, Oct 29, 2024
EPS actual
$-0.30
EPS est.
$-0.34
EPS surprise
+11.50%
1-day move
-0.44%
Est. EPS
—
Est. Rev
—
Impl. Move
—
10X Genomics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock reacted negatively, declining by 0.44%. The lack of revenue details and guidance may have contributed to investor uncertainty about the company's near-term prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | +11.50% |
| Revenue | N/A | N/A | N/A |
Management conveyed a cautiously optimistic outlook, emphasizing their commitment to innovation. They acknowledged current market challenges but remain focused on long-term growth.
Management highlighted ongoing investments in innovation and product development.
They expressed confidence in the long-term growth potential despite current challenges.
Focus remains on expanding market presence and enhancing customer engagement.